Eagle Pharmaceuticals (NASDAQ:EGRX) Share Price Passes Below 200-Day Moving Average – Should You Sell?

Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX)’s stock price crossed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $1.35 and traded as low as $0.87. Eagle Pharmaceuticals shares last traded at $1.40, with a volume of 426 shares trading hands.

Analyst Ratings Changes

Separately, StockNews.com started coverage on Eagle Pharmaceuticals in a report on Friday. They set a “hold” rating on the stock.

Eagle Pharmaceuticals Stock Performance

The stock’s 50 day moving average is $1.03 and its two-hundred day moving average is $1.35.

Institutional Investors Weigh In On Eagle Pharmaceuticals

Large investors have recently modified their holdings of the company. RBF Capital LLC lifted its position in shares of Eagle Pharmaceuticals by 11.7% during the 3rd quarter. RBF Capital LLC now owns 143,078 shares of the specialty pharmaceutical company’s stock worth $534,000 after purchasing an additional 14,991 shares during the last quarter. Jacobs Levy Equity Management Inc. purchased a new position in Eagle Pharmaceuticals in the third quarter valued at $453,000. DGS Capital Management LLC raised its stake in Eagle Pharmaceuticals by 44.9% in the third quarter. DGS Capital Management LLC now owns 71,728 shares of the specialty pharmaceutical company’s stock valued at $268,000 after buying an additional 22,239 shares in the last quarter. Finally, Jane Street Group LLC purchased a new stake in Eagle Pharmaceuticals during the 3rd quarter worth about $96,000. 85.36% of the stock is owned by hedge funds and other institutional investors.

Eagle Pharmaceuticals Company Profile

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma.